Success

Success can be measured by the quality of the transactions executed and the references that result.
Selected Portico Transaction Participants

has received a significant investment from

Portico Capital Advises HgCapital on its Investment in Evaluate Group

November 8, 2016
London, England 


Portico Capital Securities announced today that it served as the exclusive financial adviser to HgCapital on its investment in Evaluate Group, the leading provider of consensus pharmaceutical and life sciences data. Giles Roshier, Managing Director at Portico Capital, commented, “We are pleased to have advised HgCapital, a leading growth equity investor through its Mercury fund, on this transaction. With HgCapital as a partner, Evaluate is poised to expand its suite of market-leading offerings and accelerate its already impressive growth.” This transaction further demonstrates Portico’s expertise in the data and analytics sector.

Below are more details from the Company's press release:

Evaluate Ltd Receives Significant Investment from HgCapital to Expand Products and Services

LONDON, BOSTON, SAN FRANCISCO, TOKYO 8th November 2016— Evaluate Ltd, the life science commercial intelligence firm, today announced that it has received significant investment from HgCapital’s Mercury Fund to support the Company’s strategic growth plans.  Financial terms have not been disclosed.

Evaluate is the trusted source for life science commercial intelligence and analysis with exclusive consensus forecasts to 2022. It has a range of online subscription database services covering the Pharmaceutical, Biotech, and Medtech sectors. The Company also provides project-based analytical and data services and has an award-winning editorial team, EP Vantage. 

The investment from HgCapital’s Mercury Fund will enable Evaluate to strengthen its position, enabling the Company to grow its customer base and support its strategy to expand the breadth of intelligence and forecasts it provides to its customers.

Jonathan de Pass, Founder and Chairman of Evaluate, said:

“Evaluate has a first mover advantage in its market and is a leading provider in the specialist Life Sciences information publishing market. HgCapital is a good match as a strategic partner with expertise in investing in businesses such as ours. 

“These funds will enable us to accelerate our business strategy and at the same time, continue to provide the best possible market intelligence and service to our clients. We look forward to working with the HgCapital team.”

David Issott, Director of the Mercury Team, said: “Evaluate was the first company of its kind to offer such specialist intelligence services and since its inception, has had a track record of consistent growth. Our investment in Evaluate represents the Mercury team’s approach to investing into technology infrastructure businesses that occupy growing niches.  We have great confidence in the team and the business.”

Portico Capital Securities Limited served as exclusive financial adviser to HgCapital with respect to this transaction.


About HgCapital

HgCapital is a sector expert private equity investor, supporting management teams to grow industry champions. Deeply resourced sector teams focus on specific sub-sectors and investment themes to identify companies occupying an established position within a niche, and which have the potential to grow faster than their market, create employment and become the leader in their industry. HgCapital’s dedicated portfolio management team provides practical support to management teams to help them realise their growth ambitions. HgCapital invests in expanding segments of the TMT, Services, Industrials and Renewable Energy sectors across Western Europe. Based in London and Munich, HgCapital manages more than £5 billion for some of the world’s leading institutional and private investors. For more information please visit: www.hgcapital.com

About Evaluate Group

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and medtech sectors. Our Custom Services group delivers project based analytical and data services. EP Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis. For more information please visit: www.evaluategroup.com.

About Portico Capital

Portico Capital provides independent strategic and financial advisory services in the areas of mergers & acquisitions (M&A), recapitalisations and capital raisings exclusively to private and public companies in the global information and business services & software sector.  The firm, founded in 2000, has offices in Greenwich, Connecticut and London, England.

For more information, please visit www.porticocapital.com


PORTICO CONTACTS

Giles Roshier
Managing Director & Head of Europe
giles@porticocapital.com
+44 (0) 203 011 0470

Tom Burton
Vice President
tom@porticocapital.com
+44 (0) 203 011 0473